TROPION-Breast04: Dato-DXd and durvalumab in TNBC or HR-low/HER2- breast cancer

DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markersПодробнее

DESTINY-Breast04: T-DXd for patients with HER2-low mBCПодробнее

BEGONIA: durvalumab combinations in advanced TNBCПодробнее

DESTINY-Breast04: exploring T-DXd and IO combinations in HER2-low breast cancerПодробнее

Neoadjuvant Durvalumab Shows Benefit in Triple-Negative Breast CancerПодробнее

DESTINY-Breast04: practice-changing results for HER2-low breast cancerПодробнее

BEGONIA: datopotamab deruxtecan and durvalumab in metastatic triple-negative breast cancerПодробнее

BEGONIA: durvalumab + dato-DXd in advanced TNBCПодробнее

DESTINY-Breast04 Study: T-DXd Breakthrough for HER2-Low Breast Cancer TreatmentПодробнее

HER2-low expression in breast cancerПодробнее

Datopotamab deruxtecan extends PFS vs chemo for HR+/HER2- breast cancerПодробнее

DEBBRAH: T-DXd in HER2+ or HER2-low advanced breast cancer with CNS involvementПодробнее

DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1Подробнее

Dato-DXd: a new ADC on the blockПодробнее

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expressionПодробнее

Reflections on the DESTINY-Breast04 trial | Patricia LoRussoПодробнее

DESTINY-Breast04: T-DXd provides significant improvement in OS + PFS in HER2-low mBCПодробнее

TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment ArsenalПодробнее

DESTINY-Breast04: A ground-breaking trial in HER2-low breast cancerПодробнее